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The most common neuromuscular manifestation of West Nile virus (WNV) infection is a
poliomyelitis syndrome with asymmetric paralysis variably involving one (monoparesis) to
four limbs (quadriparesis), with or without brainstem involvement and respiratory failure.
This syndrome of acute ﬂaccid paralysis may occur without overt fever or meningoen-
cephalitis. Although involvement of anterior horn cells in the spinal cord and motor neurons
in the brainstem are the major sites of pathology responsible for neuromuscular signs,
inﬂammation also may involve skeletal or cardiac muscle (myositis, myocarditis), motor
axons (polyradiculitis), and peripheral nerves [Guillain–Barré syndrome (GBS), brachial plex-
opathy]. In addition, involvement of spinal sympathetic neurons and ganglia provides an
explanation for autonomic instability seen in some patients. Many patients also experi-
ence prolonged subjective generalized weakness and disabling fatigue. Despite recent
evidence that WNV may persist long-term in the central nervous system or periphery in
animals, the evidence in humans is controversial.WNV persistence would be of great con-
cern in immunosuppressed patients or in those with prolonged or recurrent symptoms.
Support for the contention thatWNV can lead to autoimmune disease arises from reports of
patients presenting with various neuromuscular diseases that presumably involve autoim-
mune mechanisms (GBS, other demyelinating neuropathies, myasthenia gravis, brachial
plexopathies, stiff-person syndrome, and delayed or recurrent symptoms). Although there
is no speciﬁc treatment or vaccine currently approved in humans, and the standard remains
supportive care, drugs that can alter the cascade of immunobiochemical events leading
to neuronal death may be potentially useful (high-dose corticosteroids, interferon prepa-
rations, and intravenous immune globulin containing WNV-speciﬁc antibodies). Human
experience with these agents seems promising based on anecdotal reports.
Keywords:West Nile virus, infection, poliomyelitis, fever
INTRODUCTION
West Nile virus (WNV), a mosquito-borne RNA ﬂavivirus and
human neuropathogen, was ﬁrst isolated from a febrile woman
in the West Nile region of Uganda, Africa in 1937 (Smithburn
et al., 1940). During the 1940s and 1950s, transmission of WNV
by mosquitoes was demonstrated, the close antigenic relationship
with ﬂaviviruses was described, and neutralizing antibody was
found in many residents of East-Central Africa (for a historical
review see Campbell et al., 2002). The virus also became recog-
nized as a cause of human meningitis or encephalitis in elderly
patients during an outbreak in Israel in 1957 (Spigland et al.,
1958), although CNS involvement in middle-aged and younger
subjects remained unusual and outcome in the younger age-group
was generally excellent (Weinberger et al., 2001). During the 1960s
to 1970s, birds were identiﬁed as a major host, horses were com-
monly infected, and there were large human epidemics in Africa
and the Middle East. Europe also experienced its ﬁrst WNV out-
break (Murgue et al., 2001). During the 1980s and 1990s, there
were major outbreaks in Africa, Middle East, Europe, and Russia,
although the Romania epidemic in 1996 marked the geographic
transition of WNVepidemics from rural areas to urban industrial-
ized areas (Campbell et al., 2002). In 1999,WNV gained entry into
North America in the New York City outbreak (Nash et al., 1999).
The viral strain introduced into the United States likely originated
from a strain that was circulating in Israel during 1998 (Lanciotti
et al., 1999). In the past decade,WNVhas spread and is nowwidely
established from Canada to Venezuela (World Health Organiza-
tion1). In 2011, human cases were reported in Albania, Greece,
Israel, Italy, Romania, Russia, and Mexico. Hence, the geographic
range of WNV now includes six of seven continents, including
Africa, Asia, Europe, Australia (subtype Kunjin), North America,
and South America.
Before 1996, WNV was known to cause high fever, chills,
malaise, headache, backache, arthralgia, myalgias, retro-orbital
pain, and a maculopapular rash, but neurological symptoms were
uncommon. However, since the New York City outbreak, severe
neurological illness, including encephalitis and meningitis, has
been reported much more frequently, together with neuromus-
cular manifestations. The diagnosis of WNV infection should be
considered in any patient with an unexplained acute febrile or
neurological illness during the summer months, particularly if
recently exposed to mosquitoes. In such cases, serum should be
tested for classM immunoglobulin (IgM) antibody toWNV,which
1http://www.who.int/mediacentre/factsheets
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indicates a recent infection. If there are signs of CNS involvement,
cerebrospinal ﬂuid (CSF) should be analyzed and also tested for
WNV IgM antibody. CSF ﬁndings typically show increased leuko-
cytes (usually >200 cells/mm3), increased protein, and normal
glucose. Almost half of WNV meningitis patients may have at
least 50% neutrophils in their initial CSF specimen (Tyler et al.,
2006), followed by a shift to lymphocytosis. Imaging studies in
WNV infection are frequently normal, although theymaybeuseful
in excluding other etiologies of acute myelomeningoencephalitis.
When abnormal, ﬁndings are generally non-speciﬁc and without
mass effect. T2-weighted magnetic resonance signal abnormali-
ties have been reported in brainstem, deep gray structures (basal
ganglia or thalami), and cerebellum (Petropoulou et al., 2005).
However, other imaging series have found no deﬁnite predilection
for any speciﬁc area of the brain parenchyma (Ali et al., 2005).
In patients with WNV-associated limb paralysis, abnormal sig-
nal intensity may be more pronounced in the spinal cord ventral
horns with enhancement around the conus medullaris and cauda
equina (Petropoulou et al., 2005). However, follow-up MRIs may
show complete resolution of signal abnormalities.
Neuromuscular manifestations are now recognized as a
prominent feature in patients with WNV neuroinvasive disease
(encephalitis, meningitis). In the 1999 New York City outbreak,
more than 50% of patients with conﬁrmed WNV encephalitis had
severemuscleweakness as a cardinal sign (Nash et al., 1999).Weak-
ness was an apparent risk factor predicting death in patients with
WNV encephalitis (Nash et al., 1999; Petersen and Marﬁn, 2002).
In the 2002 and 2003 WNV epidemics in the United States, neuro-
muscular manifestations were a well-recognized feature associated
with increased morbidity and mortality (Jeha et al., 2003). In Col-
orado, the state with the most reported cases of WNV infection
(2,943) and fatalities (63) during the 2003 epidemic, as many as
50% of patients with encephalitis had evidence of acute ﬂaccid
paralysis (Tyler, 2004).
WEST NILE VIRUS POLIOMYELITIS
In the original New York City outbreak, several case series
attributedneuromuscular complications,particularly acute ﬂaccid
paralysis, to peripheral neuronal processes, namely Guillain–Barré
syndrome (GBS), motor axonopathy, or severe axonal polyneu-
ropathy (Nash et al., 1999; Asnis et al., 2000; Sampson et al., 2000).
In the 2002 epidemic, more cases of WNV-associated acute ﬂaccid
paralysis were also seen across the Southern United States. These
patients had asymmetric acute ﬂaccid paralysis, absent deep ten-
don reﬂexes in affected limbs, preserved sensation, bowel, or blad-
der dysfunction, and respiratory distress. Electrodiagnostic studies
in these subjects revealed markedly decreased or absent motor
responses in the paretic limbs, preserved sensory responses, and
widespread asymmetric muscle denervation, without evidence of
demyelination or myopathy. The clinical and electrodiagnostic
ﬁndings were classic for poliomyelitis and inconsistent with GBS
or other peripheral nerve disorders. These cases were reported in
the Centers for Disease Control Morbidity and Mortality Weekly
Report on September 20, 2002 (Centers for Disease Control and
Prevention, 2002), with clinical, laboratory, and electrophysio-
logic guidelines to help physicians discern poliomyelitis from GBS
(Table 1). Subsequently, clinical, laboratory, and neurophysiologic
ﬁndings suggested thatWNV-associated acute ﬂaccid paralysis was
a poliomyelitis syndrome with involvement of anterior horn cells
of the spinal cord (Glass et al., 2002; Leis et al., 2002; Li et al.,
2003; Al-Shekhlee and Katirji, 2004). Soon thereafter pathologic
conﬁrmation of WNV poliomyelitis (Figures 1A–C) was provided
by several groups (Doron et al., 2003; Jeha et al., 2003; Kelly et al.,
2003; Leis et al., 2003a; Fratkin et al., 2004; Guarner et al., 2004).
Our postmortem examinations of four patients with WNV infec-
tion from the 2002 epidemic,who developed muscle weakness and
acute respiratory distress, showed that poliomyelitis was the major
CNS ﬁnding in each case (Leis et al., 2003a; Fratkin et al., 2004).
This is in agreement with the neuropathology of experimental
or naturally occurring WNV infection in monkeys (Manuelidis,
1956), horses (Cantile et al., 2000, 2001), and birds (Steele et al.,
2000). In these vertebrates,WNV shows a pronounced tropism for
gray matter of the spinal cord, causing poliomyelitis. In contrast,
peripheral nerves are not commonly involved.
Most investigators actively involved in WNV clinical research
now accept poliomyelitis to be the most common cause of WNV-
associated acute ﬂaccid paralysis in humans. Moreover, the CDC
now classiﬁes WNV infection into WNV fever or neuroinvasive
Table 1 | Characteristics inWest Nile virus-associated poliomyelitis compared with typical Guillain–Barré syndrome.
West Nile poliomyelitis Guillain–Barré syndrome
Timing of onset Acute phase of infection Weeks after acute infection
Fever, leukocytosis Present Absent
Weakness distribution Asymmetric; monoplegia to quadriplegia Generally symmetric; proximal and distal muscles
Sensory symptoms Some myalgias, infrequent numbness, paresthesias, or sensory loss Sensory loss, painful distal paresthesias
Bowel and bladder Often involved Rarely involved
Encephalopathy Often present Absent
CSF proﬁle Pleocytosis, elevated protein No pleocytosis, elevated protein (albuminocyto-
logic dissociation)
Electrodiagnostic features Anterior horn cell or motor axon loss (reduced/absent CMAPs,
preserved SNAPs, asymmetric denervation)
Demyelination (marked slowing of conduction
velocity, conduction block, temporal dispersion);
reduced SNAPs
CSF, cerebrospinal ﬂuid; CMAP, compound muscle action potential; SNAP, sensory nerve action potential.
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disease,with further subdivision of the latter group into encephali-
tis, meningitis, and poliomyelitis. Patients with the poliomyelitis
presentation commonly have associated signs of meningitis,
FIGURE 1 | Spectrum of pathological findings inWest Nile virus
poliomyelitis: (A) Chromatolytic neuron with eccentric nucleus and
distended cell body. Chromatolysis is usually triggered by damage to the
cell body or axon. Neuronal recovery through regeneration can occur after
chromatolysis, but most often it is a precursor of cell death (apoptosis). The
event of chromatolysis is also characterized by a prominent migration of the
nucleus toward the periphery of the cell and increase in the size of the cell
body (hematoxylin–eosin, original magniﬁcation ×400); (B) Activated
microglial cells surround and ingest a dead neuron (neuronophagia), which is
typical of viral infections (hematoxylin–eosin, original magniﬁcation ×400);
(C) Blood vessel at the interface between ventral horn gray matter and
adjacent white matter surrounded by a dense cuff of chronic inﬂammatory
cells (perivascular inﬂammation); wm, white matter; gm, gray matter
(hematoxylin–eosin, original magniﬁcation ×100); (D) Cervical sympathetic
ganglia. Microglial nodules are clustered around eosinophilic husks of dying
ganglion cells. Microglial cells are consuming the pyknotic sympathetic
neurons (neuronophagia; hematoxylin–eosin, original magniﬁcation ×400).
encephalitis, or respiratory distress from involvement of spinal
motor neurons supplying the phrenic nerves to the diaphragm,
but acute ﬂaccid paralysis also may occur in the absence of fever
or meningoencephalitis (Leis et al., 2003b; Li et al., 2003; Sej-
var et al., 2003). Recovery from neurological sequelae of WNV
neuroinvasive disease may be slow and incomplete (Davis et al.,
2006), with a poorer prognosis for recovery of physical function
in patients with acute ﬂaccid paralysis (Johnstone et al., 2011).
Our initial four patients in 2002 with acute ﬂaccid paralysis and
profound loss of anterior horn cells in paretic limbs based on
electrodiagnostic studies (CDC 2002; Leis et al., 2002) remain
weak in affected limbs almost a decade after the acute WNV
illness. However, each of these patients had needle electromyo-
graphic (EMG) evidence of profound denervation in muscles
of the most affected limbs with few or no voluntarily recruited
motor unit potentials (MUPs) and absent or markedly reduced
motor responses with normal sensory responses on nerve con-
duction studies. Table 2 shows motor and sensory amplitudes in
one of these patients, a 50-year-old man with WNV poliomyelitis
limited to the right upper limb. Follow-up nerve conduction
studies at 3-, 6-, and 12-month continued to show markedly
reduced motor responses in proximal muscles with normal sen-
sory responses. Follow-up needle EMG examinations also showed
persistent profound denervation in shoulder girdle muscles with
only a single voluntarily recruited MUP in deltoid and biceps
(Figure 2). This patient never regained the ability to abduct or
forward elevate the arm past the horizontal position. In contrast,
limbs with lesser degrees of anterior horn cell loss, based on the
presence of recordable motor responses and preserved innerva-
tion on needle EMG, had better recovery of function. Indeed,
our observations after performing electrodiagnostic evaluations
on many WNV patients with varying degrees of acute ﬂaccid
paralysis suggest that prognosis for recovery of function is greatly
dependent on the degree of motor neuron loss; limbs with absent
motor responses and no voluntary EMG activity have a poorer
long-term prognosis while those with relatively preserved motor
Table 2 | Baseline-to-peak amplitudes of motor (m, in mV) and sensory (s, in μV) responses in a 50 year-old man withWest Nile poliomyelitis of
right upper limb.
Nerve Stimulation
site
Recording
site
Initial
study
3-month
follow-up
6-month
follow-up
12-month
follow-up
Normal
values
R L R L R L R L
Median (m) Wrist APB 2.0 11.4 3.8 11.2 6.3 – 8.4 12.7 ≥5.0
Median (s) Wrist Digit II 33.4 35.4 27.2 32.8 38.1 – 34.0 37.3 ≥20.0
Ulnar (m) Wrist ADM 1.6 7.5 2.1 12.1 3.9 – 5.6 14.0 ≥4.5
Ulnar (s) Wrist Digit V 28.8 27.6 21.8 23.5 30.7 – 29.2 28.0 ≥15.0
Musculocutaneous (m) Erb’s point Biceps 0.2 7.6 0.2 7.0 0.6 – 2.0 11.6 ≥4.0
Musculocutaneous (s) Arm Forearm 27.1 32.6 21.4 – 22.0 – 18.6 19.5 ≥10.0
Axillary (m) Erb’s point Deltoid 0.4 5.3 0.2 7.3 1.4 – 2.8 13.4 ≥4.0
Radial (s) Forearm Dorsum hand 31.9 31.8 39.8 40.3 39.4 – 34.8 44.5 ≥15.0
He initially presented with acute ﬂaccid paralysis and areﬂexia in the right arm, without pain or paresthesias. Sensory examination was normal. Initial electrodiagnostic
studies showed markedly reduced motor responses in the monoplegic right limb (particularly in proximal muscles), with normal sensory responses. Note persistently
reduced proximal motor responses 1 year after the acute illness.
R, right; L, left; APB, abductor pollicis brevis; ADM, abductor digiti minimi; bold data are abnormal.
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FIGURE 2 | Electromyographic (EMG) examination in a
50-year-old man withWNV poliomyelitis limited to the right
upper limb. Needle examination of the biceps muscle at 1 year
follow-up showed persistent profound denervation with only a single
voluntarily recruited rapidly ﬁring motor unit potential. Similar
denervation was noted in other shoulder girdle muscles. Clinical
follow-up 5 years later revealed persistent severe weakness in
proximal upper limb muscles.
responses and some voluntary activity have a more favorable
outcome.
OTHER SPINAL CORD NEUROPATHOLOGY IN WEST NILE
VIRUS INFECTION
Although the anterior horns are the major site of spinal cord
pathology (Kelly et al., 2003; Leis et al., 2003a; Fratkin et al., 2004),
autopsy series show that pathologic changes may extend beyond
the spinal cord gray matter with focal inﬂammatory changes
involving the adjacent white matter (Fratkin et al., 2004). This may
explain the infrequent occurrence of WNV-associated transverse
myelitis with clinical involvement of spinal sensory and motor
pathways (Leis, personal observation). In addition, neuronopha-
gia, neuronal disappearance, and pathologic alterations have been
described in dorsal root ganglia and sympathetic ganglia (Fratkin
et al., 2004). Involvement of dorsal root ganglia may explain some
of the sensory deﬁcits and reduced sensory nerve action poten-
tials on electrodiagnostic testing that occasionally are reported
in patients with WNV infection (Doron et al., 2003; Jeha et al.,
2003). However, sensory loss attributed to WNV has not been a
prominent clinical ﬁnding.Another oftenoverlookedﬁnding is the
disappearance of neurons in the sympathetic ganglia (Figure 1D),
which offers a plausible explanation for the autonomic instability
observed in some patients, including labile vital signs, hypoten-
sion, and potentially lethal cardiac arrhythmias (Pepperell et al.,
2003; Fratkin et al., 2004; Bode et al., 2006). In rodents, WNV can
lead to autonomic dysfunction by infecting neurons controlling
cardiac and gastrointestinal function (Wang et al., 2011). These
data lead to hypothesis that autonomic instability may play a role
in the morbidity and mortality of human WNV infection.
WEST NILE VIRUS SPINAL NERVE ROOT INVOLVEMENT
Inﬂammatory changes in spinal cord gray matter also may extend
into the spinal nerve roots to cause a myeloradiculitis (Jeha et al.,
2003; Bouffard et al., 2004). Involvement of ventral spinal roots
may contribute to the asymmetric acute ﬂaccid paralysis seen in
many patients with WNV infection. Magnetic resonance imaging
ﬁndings showing apparent enhancement of ventral nerve roots
support the concept that anterior radiculopathy should be con-
sidered, in addition to anterior horn cell pathology, when assess-
ing patients with WNV-associated acute ﬂaccid paralysis (Park
et al., 2003). However, acute isolated radiculopathy as the sole
neuromuscular manifestation of WNV infection is not common,
although confusion may arise when acute ﬂaccid paralysis attrib-
utable to poliomyelitis is limited to one limb (monoparesis; Leis
et al., 2003b). In one series that included 10 patients with WNV
poliomyelitis, 4 patients hadmonoparesis (Emig andApple, 2004).
We have also encountered several patients with WNV and asym-
metric weakness in the arms or legs who initially were thought to
have cervical or lumbosacral radiculopathies (Leis et al., 2002; Leis
and Stokic, 2005).
WEST NILE VIRUS PERIPHERAL NERVE INVOLVEMENT
West Nile virus can involve peripheral nerves although this man-
ifestation is much less frequent than originally assumed during
the 1999 outbreak, when weakness and acute ﬂaccid paralysis
were attributed to GBS or axonal polyneuropathy (Nash et al.,
1999; Asnis et al., 2000; Sampson et al., 2000). In 1 series of
64 patients with WNV infection, 3 patients had mixed axonal
degenerating and demyelinating processes, and 1 had a pure
demyelinating neuropathy (Pepperell et al., 2003). In addition,
there are case reports of patients with true GBS (Ahmed et al.,
2000; Xu et al., 2003; Sejvar et al., 2004), unilateral brachial
plexopathy (Almhanna et al., 2003; Sejvar et al., 2004), and bilat-
eral diaphragmatic paralysis attributed to loss of motor neurons
or motor axons supplying the phrenic nerves (Betensley et al.,
2004). Lymphocytic inﬁltration of nerves and occasional degen-
erating axons also has been described (Li et al., 2003; Smith et al.,
2004), prompting a suggestion that WNV may reach the CNS
via peripheral nerves (Smith et al., 2004). Indeed, recent evidence
suggests that axonal transport mediates WNV entry into the CNS
and induces acute ﬂaccid paralysis (Samuel et al., 2007). How-
ever, most autopsy series do not suggest that WNV exhibits a
predilection for peripheral nerves. Similarly, WNV infection in
monkeys (Manuelidis, 1956), horses (Cantile et al., 2000, 2001),
and birds (Steele et al., 2000) does not commonly involve periph-
eral nerves. In addition, it should be recognized that prolonged
critical illness can be associated with an axonal sensorimotor
polyneuropathy, termed critical illness polyneuropathy (Hund,
2001), which can confound the interpretation of WNV-associated
polyneuropathy.
NEUROMUSCULAR JUNCTION AND SKELETAL MUSCLE IN
WEST NILE VIRUS INFECTION
West Nile virus has not been reported to cause a defect in neu-
romuscular transmission, but we have encountered three patients
Frontiers in Neurology | Neuromuscular Diseases March 2012 | Volume 3 | Article 37 | 4
Leis and Stokic West Nile virus infection
with WNV poliomyelitis who developed classic myasthenia gravis
with positive acetylcholine receptor antibodies and a marked
decremental response on repetitive nerve stimulation studies (ini-
tial case reported in Leis and Stokic, 2005). We also are aware
of the association of WNV and myasthenia gravis in two other
patients (personal communication). Myopathy also is an uncom-
mon manifestation of WNV infection, although there are several
reports of rhabdomyolysis with creatine kinase levels as high as
45,000U/L (normal <220U/L; Doron et al., 2003; Jeha et al.,
2003; Gupta et al., 2008). However, in one of these reports, post-
mortem examination conﬁrmed poliomyelitis with striking loss of
motor neurons in the anterior horn and brainstem, and only mild
inﬂammation without necrosis in skeletal muscle (Doron et al.,
2003). In another series, muscle biopsies on four patients with
WNV with acute asymmetric paralysis showed scattered necrotic
muscle ﬁbers invaded by macrophages (two patients), normal
muscle ﬁbers with inﬂammatory cells surrounding small blood
vessels (one patient), and a normal muscle biopsy (one patient; Li
et al., 2003). In one of the patients with scattered necrotic muscle
ﬁbers, immunohistochemistry with polyclonal antibodies against
ﬂaviviruses did not detect WNV on biopsied muscle. These inves-
tigators acknowledged that the scattered necrotic muscle ﬁbers
were an unlikely explanation for the severe paralysis observed (Li
et al., 2003). In the most comprehensive series of rhabdomyolysis
in patients with WNV neuroinvasive disease, 9 of 244 hospi-
talized patients had rhabdomyolysis (median age 70 years, CK
levels ranged from 1,153 to 42,113 IU; Montgomery et al., 2005).
However, six of nine patients had history of recent falls prior
to admission. The authors concluded that although the tempo-
ral relationship of rhabdomyolysis and WNV illness suggested a
common etiology, these patients presented with complex clinical
conditions that may have led to development of rhabdomyoly-
sis from other causes (Montgomery et al., 2005). In addition, it
is now commonly recognized that critical illness can be associ-
ated with a diffuse myopathy, termed critical illness myopathy,
which can cause generalized weakness, respiratory failure, and
inability towean fromthe respirator (Lacomis et al., 2000).Accord-
ingly, the role played by direct WNV invasion of muscles and the
clinical signiﬁcance of WNV-associated myositis remains to be
elucidated.
West Nile virus has also been reported to cause myocarditis
(Braun et al., 2006; Kushawaha et al., 2009) and cardiomyopathy
(Khouzam,2009),which can predispose to fatal arrhythmia. How-
ever, cardiac arrhythmias have also been reported to occur across
the spectrum of WNV disease, including in cases of WNV fever
not associated with myocarditis (Bode et al., 2006). Since statis-
tics on the incidence of WNV myocarditis as the cause of cardiac
arrhythmias are lacking, it is possible that autonomic instability
caused by direct WNV infection of neurons controlling cardiac
function (Fratkin et al., 2004; Wang et al., 2011) may also have
precipitated cardiac arrhythmias.
WEST NILE VIRUS AND AUTOIMMUNE DISEASE
An unresolved issue that may have important neuromuscular
implications is whether WNV infection can induce autoimmune
disease (Leis and Stokic, 2005). Support for this contention
arises from the numerous reports of WNV patients with various
neuromuscular diseases that have a presumed autoimmune mech-
anism, including GBS (Ahmed et al., 2000; Xu et al., 2003; Sejvar
et al., 2004, 2005), other demyelinating neuropathies (Pepperell
et al., 2003; Sumner and Jones, 2008), myasthenia gravis (Leis and
Stokic, 2005), brachial plexopathies (Almhanna et al., 2003; Sej-
var et al., 2004), and stiff-person syndrome (Hassin-Baer et al.,
2004). In the latter case, stiff-person syndrome with antibod-
ies to glutamic acid decarboxylase developed several weeks after
WNV fever. CNS vasculitis with acute stroke or loss of vision
due to WNV infection has also been reported (Kaiser et al., 2003;
Kulstad and Wichter, 2003; Lowe et al., 2005). There is also exper-
imental evidence that WNV causes a signiﬁcant upregulation of
class I and II major histocompatibility complex (MHC) mole-
cules in Lewis rat Schwann cells (Argall et al., 1991). Moreover,
irradiated medium from WNV-infected Schwann cell cultures
upregulated class I molecule expression on dissociated Schwann
cell cultures. These ﬁndings were considered to have implica-
tions for virally triggered autoimmune disease of nervous tissue.
Infection of human embryonic myoblasts by WNV also causes
a signiﬁcant upregulation of class I and II MHC expression
(Bao et al., 1992). MHC class I was increased after exposure to
virus-inactivated supernatant from infected cells, indicating the
presence of additional factors contributing to the MHC class I
increase. The investigators concluded that these ﬁndings may be
important in establishing a link between viral infection of human
cells and induction of inﬂammatory autoimmune myositis (Bao
et al., 1992). Other studies have shown that WNV can regu-
late the cell surface expression of numerous immune recognition
molecules, resulting in increased recognition by WNV-speciﬁc
and allo-speciﬁc cytotoxic T cells (Kesson et al., 2002). How-
ever, long-term follow-up of patients with WNV infection should
clarify whether there is an increased incidence of autoimmune
diseases.
PERSISTENCE OF WEST NILE VIRUS IN THE HUMAN BODY
Acute WNV infection is usually cleared by an effective immune
response after several days of viremia. Recent evidence, however,
suggests thatWNVmay persist long-term in animals (Appler et al.,
2010) and humans (Murray et al., 2010). Immunocompetent mice
inoculated with WNV showed infectious virus or WNV RNA
in the CNS and periphery for up to 6months post-inoculation
(Appler et al., 2010). Viral persistence occurred in the face of a
robust antibody response and in the presence of inﬂammation in
the brain. Furthermore, persistence in the CNS and pathological
evidence of encephalitis were observed even in mice with subclin-
ical infections. In such cases, the CNS immune response appears
to be ineffective in clearing the virus (Stewart et al., 2011). In
humans, WNV RNA was recently demonstrated in 5 (20%) of 25
urine samples collected from convalescent WNV patients diag-
nosed with WNV neuroinvasive disease between 2002 and 2007
(Murray et al., 2010). However, attempts to grow the virus from
urine of these ﬁve patients were not successful. These ﬁndings
suggest that in some individuals, WNV RNA may persist for sev-
eral years after infection. These results may also have implications
for some WNV-infected humans, particularly immunosuppressed
patients or thosewith long-termor recurrent sequelae. Conversely,
a subsequent study failed to demonstrate WNV RNA in urine
www.frontiersin.org March 2012 | Volume 3 | Article 37 | 5
Leis and Stokic West Nile virus infection
samples collected from an established cohort of 40 persons over
6 years after initial infection with WNV. Urine from all partic-
ipants tested negative for WNV RNA by reverse-transcription
polymerase chain reaction and transcription-mediated ampliﬁ-
cation (Gibney et al., 2011). These conﬂicting ﬁndings suggest
that prospective studies are needed to determine if and for how
long WNV may persist in urine or other tissues following acute
infection.
SPECTRUM OF NEUROMUSCULAR SYMPTOMS AND SIGNS
IN WEST NILE VIRUS INFECTION
Inour initial series of 54WNVpatients from2002 to 2006,whohad
extensive electrodiagnostic evaluation and four autopsies, neu-
romuscular manifestations included: acute ﬂaccid paralysis with
electrophysiologic or pathologic features of poliomyelitis (n = 23),
clinical ﬁndings of autonomic instability (cardiac dysrhythmias,
marked ﬂuctuations in blood pressure, gastrointestinal complica-
tions including gastroparesis) or pathologic alterations in sym-
pathetic ganglia (n = 8), brainstem dysfunction (n = 4) including
three cases of seventh nerve palsies (two delayed several weeks after
acute illness and one with acute illness), myopathy (n = 3, in two
attributed to critical illness myopathy and one case of rhabdomy-
olysis with acute renal failure),newonsetmyasthenia gravis (n = 3,
one case diagnosed in 2011),diffuse axonal polyneuropathy (n = 2,
one attributed to critical illness polyneuropathy and one to acute
polyneuropathy associated with WNV), transverse myelitis with
involvement of sensory and motor pathways (n = 1), gait apraxia
(n = 1), and optic nerve involvement (n = 1). In the latter case,
full-ﬁeld pattern reversal visual evoked potential studies showed
a monocular abnormality that suggested a conduction defect in
the visual pathways anterior to the optic chiasm. In nine patients,
the chief complaint was severe or disabling fatigue without objec-
tive muscle weakness on clinical examination or abnormalities on
neurophysiologic studies. The speciﬁc physiologic mechanism for
WNV fatigue remains unknown.Aside from the psycho-social fac-
tors, residual dysfunction in anterior horn cells and involvement
of brainstem reticular activating system may play a role. In the
post-polio syndrome, poliovirus-induced lesions in the reticular
activating systemare thought to contribute to the subjective fatigue
(Bruno et al., 1994). In patients with WNV infection, prolonged
fatigue is common after the acute illness (Campbell et al., 2002),
affecting nearly two-thirds of patients. At 1 year follow-up, fatigue
was the most common persistent symptom in patients hospital-
ized from the 1999 New York outbreak, affecting 67% of patients
whereas muscle weakness was found in 44% of patients (New
York Department of Health, 2001; Petersen and Marﬁn, 2002).
Thus, physicians should be aware that fatigue and subjective weak-
ness may be the major complaint in patients with WNV infection,
particularly in those with WNV fever.
In addition, we observed two patients that developed severe,
but reversible, muscle weakness that recovered completely within
weeks. Both patients were hospitalized for their weakness. Weak-
ness involved both lower limbs in one patient (paraparesis) and
one upper limb in the other (monoparesis). Their neurophysi-
ologic studies were unremarkable after recovery of function, in
agreement with the clinical examination. The reversible muscle
weakness likely reﬂects transient anterior horn cell dysfunction
during the phase of acuteWN illness,with full recovery of function
occurring within several weeks. Although rapid reversal of paraly-
sis has rarely been reportedwithWNV infection, this phenomenon
is not new, and was ﬁrst observed in patients with poliomyelitis
caused by the poliovirus (Paul, 1971). Jacob von Heine (1799–
1878) recognized the transitory nature of some attacks of paralysis
early in the nineteenth century, and attributed the rapid improve-
ment to ﬂuid exudate and edema in the spinal cord that was
reabsorbed (Paul, 1971). Therefore, in acute WNV infection, as in
acute poliovirus infection, reversible paralysismay reﬂect transient
anterior horn cell dysfunction. Two other patients developed exag-
gerated weakness in the distribution of preexisting lower motor
neuron dysfunction after WNV infection. One of these patients
developed persistent weakness limited to the same leg that had
been symptomatic 14 years earlier from spinal stenosis caused by
a synovial cyst. Another patient had a four-level lumbar laminec-
tomy in 2001 for spinal stenosis that caused weakness, pain, and
altered sensation in the right more than left leg. After surgery,
symptoms improved although tingling persisted in the right leg.
After acute WNV illness 11months later, the patient reported dis-
abling fatigue and exaggerated weakness in the same distribution
as the preexisting weakness. In these patients, the observation that
WNV infection caused exaggerated weakness in the previously
weak limbs suggests that preexisting dysfunction may predispose
anterior horn cells to additional injury during acute WNV infec-
tion. It is speculated that anterior horn cells that have survived
an initial insult, or incorporated too many muscle ﬁbers from
denervated motor units beyond the metabolic capability, may be
especially prone to injury (Leis et al., 2003b).
WEST NILE VIRUS IMMUNITY AND PATHOGENESIS
Although postmortem examinations have conﬁrmed WNV
poliomyelitis and encephalitis, including patchy infection of neu-
rons in the cerebral cortex, hippocampus, basal ganglia, cerebel-
lum, and brain stem (Doron et al., 2003; Kelly et al., 2003; Leis
et al., 2003a; Fratkin et al., 2004; Guarner et al., 2004), the pre-
cise mechanisms that underlie destruction of neurons remain to
be fully elucidated. The increased risk of severe WNV infection
in immunosuppressed and elderly patients suggests that an intact
immune system is essential for control of WNV. WNV-speciﬁc
antibodies are responsible for reducing viremia and preventing
development of severe disease, while different T-lymphocyte pop-
ulations play an important role in clearing infection from tissues
and preventing viral persistence (Lim et al., 2011). However, the
pathologic effect of the immune system in WNV neuroinvasive
disease cannot be overlooked. Studies with a neuroadapted strain
of Sindbis virus, a related RNAneurotropic virus capable of induc-
ing death of spinal motor neurons in rodents resulting in acute
ﬂaccid hind-limb paralysis, revealed that many degenerating neu-
rons were not directly infected with the virus (Jackson et al.,
1988; Havert et al., 2000; Darman et al., 2004). Rather, bystander
neuronal death occurred as a result of a cascade of immuno-
biochemical events in the spinal cord that impaired glutamate
transport and allowed excess glutamate to accumulate extracel-
lularly around motor neurons. This excess synaptic glutamate is
boundby calciumpermeable glutamate receptors onpost-synaptic
motor neurons, causing the excitotoxic destruction of that neuron,
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whether it harbored the virus or not (Darman et al., 2004). WNV
neuroinvasive disease is also characterized by increased produc-
tion of pro-inﬂammatory cytokines derived from infected cells
(Kumar et al., 2010) and upregulation of other pro-inﬂammatory
genes (van Marle et al., 2007). These cytokines and other pro-
inﬂammatory factors are either neurotoxic or attract leukocytes
into the affected area, which further contribute to WNV-induced
neurotoxicity. Hence, WNV-induced inﬂammation is now recog-
nized as a major contributor of neuropathogenesis. The concept
of a pathologic effect of the immune system in WNV neuroin-
vasive disease provides a framework for the development of anti-
inﬂammatory drugs as much needed interventions to limit the
cascade of immunobiochemical events leading to neurotoxicity
(Kumar et al., 2010).
TREATMENT FOR NEUROINVASIVE WEST NILE INFECTION
At present, no speciﬁc therapy has been approved for human use
in WNV infection. However, the merging knowledge about the
pathogenesis of WNV infection has direct therapeutic implica-
tions. Treatment strategies that control the previously described
cascade of events leading to neuronal death may prove beneﬁcial.
Promising therapies include the use of interferon and interferon
inducers, which have been shown to reduce mortality in mice
infected by subcutaneous injection of WNV (Morrey et al., 2004).
A preliminary report described three WNV patients with neuro-
logic syndromes who showed improvement after receiving inter-
feron alpha, thereby increasing optimism toward this treatment
(Sayao et al., 2004). Interferon gamma producing gamma-delta T
cells also have been shown to preventmortality frommurineWNV
infection (Wang et al., 2003).Other potential therapies include rib-
avirin, nucleic acids, RNA interference, antisense oligomers, pep-
tides, imino sugars, and mycophenolic acid (for a review, see Dia-
mond, 2009). These agents act through distinct mechanisms and
are moving through various stages of pre-clinical development.
The role of corticosteroids in WNV neuroinvasive disease is
controversial, with concern that immunosuppressive effects may
worsen outcome. However, high-dose steroids have been used
to successfully treat a patient with WNV-associated acute ﬂac-
cid paralysis (Pyrgos and Younus, 2004). In addition, ﬁndings
in 14 patients with acute infection suggest that intravenous dex-
amethasone may be the reason for shortening the acute phase
of WNV meningoencephalitis and hastening patient recovery
(Narayanaswami et al., 2004). We also have administered high-
dose intravenous steroids to two patients with acute ﬂaccid paral-
ysis and brainstem involvement, including progressive seventh
nerve palsies, who showed clear improvement in brainstem symp-
toms and facial paralysis within 24 h of treatment. However, both
cases were characterized by an atypical temporal pattern of pro-
gressive symptoms or new deﬁcits occurring several weeks after
the onset of the acute illness. In most cases, WNV is thought
to be cleared by an effective immune response after only several
days of viremia. Accordingly, this relatively delayed progression
of symptoms is more likely to reﬂect secondary injury from the
downstream cascade of excitotoxic events and a secondary wave
of inﬂammation. In cases where the temporal course suggests that
indirect immune-mediated mechanisms may be contributing to
neuronal injury, a trial of high-dose corticosteroids seems justiﬁed.
There also has been great interest in passive immunization with
intravenous immune globulin (IVIG) for the treatment of patients
with acute WNV infection. Immune serum frequently was used
in the pre-antibiotic era to treat infectious diseases, and animal
data indicate an important role for humoral immunity in con-
trolling WNV infection (Gea-Banacloche et al., 2004). Given the
endemic nature of WNV in the Middle East, IVIG obtained from
Israeli blood donors that contains WNV-speciﬁc antibodies pro-
vided clear-cut protection to animals treated before or shortly after
infectious challenge with WNV (Ben-Nathan et al., 2003). In con-
trast, IVIG obtained from blood donors from the United States
without WNV-speciﬁc antibodies had no similar protective effect
(Ben-Nathan et al., 2003). Several case reports also show efﬁcacy
of IVIG containing WNV-speciﬁc antibodies in aborting human
WNV infection (Hamdan et al., 2002;Agrawal andPeterson,2003),
although other case studies found no clear beneﬁt (Haley et al.,
2003). A double-blind placebo-controlled multicenter trial was
initiated in 2003 to compare the efﬁcacy of an Israeli IVIG prepa-
ration that had a high-titer anti-WNV antibody (Omr-IgG-am;
Omrix, Tel Aviv) with that of U.S. IVIG (Polygam; Baxter Health-
careCorp.,Deerﬁeld, IL,USA),which lacked detectable anti-WNV
antibody.However, the study did not enroll enough cases to permit
data analysis in the 2003 epidemic season. Nonetheless, neutral-
izing antibody therapeutics show promise in inhibiting WNV
infection and preventing acute ﬂaccid paralysis in vivo (Diamond,
2009), which justiﬁes phase I and II studies using humanized or
human monoclonal antibodies.
DIFFERENTIAL DIAGNOSIS OF NEUROINVASIVE WEST NILE
INFECTION
Our observations and literature review suggest that patients with
WNV infection who have muscle weakness or other neuromus-
cular signs and symptoms often are given erroneous diagnoses
and may receive inappropriate, potentially injurious treatments.
Among patients referred to our rehabilitation center with WNV
neuroinvasive disease, initial diagnoses that ultimately proved tobe
erroneous included evolving stroke, GBS, myopathy, food poison-
ing, endocarditis, sepsis, heat stroke, malingering, gastroenteritis,
drug reaction, spinal cord compression, diabetic amyotrophy, and
myocardial infarction. Diagnostic studies and therapies directed at
these erroneous diagnoses are typically ineffective and canproduce
signiﬁcant morbidity. Hence, physicians should consider a diag-
nosis of WNV infection in any patient who presents with a febrile
illness that progresses over several days associated with neurologi-
cal signs or symptoms, especially during the summer months (i.e.,
“summer ﬂu”plus neurological symptoms). Health care providers
also need to be aware that the spectrum of neuromuscular mani-
festations may range from a poliomyelitis syndrome in the absence
of overt fever or meningoencephalitis to subjective weakness and
disabling fatigue. This awareness will help to avoid less tenable
diagnoses and inappropriate treatment.
The differential diagnoses of WNV infection include other
arbovirus encephalitides (e.g., St. Louis encephalitis virus, Japan-
ese encephalitis virus, Eastern, Western, and Venezuelan equine
encephalitis viruses, tick borne encephalitis virus), other viral
meningoencephalitides (La Crosse virus, Murray Valley virus,
coxsackievirus, echovirus, enterovirus), bacterial meningitis or
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encephalitis (including Lyme disease and Leptospirosis), tick
paralysis, and non-infectious conditions that affect brain or spinal
cord (e.g., stroke, brain or spinal cord tumors, spinal cord com-
pression). Guillian–Barre syndrome and other immune-mediated
neuropathies are also diagnostic considerations, since in some
casesWNV poliomyelitis may mimic these disorders (see Table 1).
Poliovirus poliomyelitis should also be considered in the differen-
tial diagnosis if the patient resides in or travels to a polio-endemic
region. However, in 2011 only four countries (India, Afghanistan,
Nigeria, and Pakistan) remain polio-endemic (see text footnote 1).
In addition, poliovirus infection mainly affects infants or young
children.
CONCLUDING REMARKS
Although anterior horns are the major site of spinal cord pathol-
ogy, inﬂammatory changes may also involve muscle ﬁbers, periph-
eral nerves, spinal roots, and spinal sympathetic neurons and
ganglia, contributing to the wide spectrum of neuromuscular
manifestations of WNV infection. Unresolved issues with impor-
tant implications include whether WNV may persist in the CNS
or periphery, and whether WNV infection may lead to autoim-
mune disease. Although there is no speciﬁc treatment or vaccine
approved for human WNV infection, several drugs that can alter
the cascade of immunobiochemical events leading to neuronal
death may be potentially useful.
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